Mesenchymal Stem Cell Apoptotic Bodies for Cognitive Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods are inadequate in preventing or reducing cognitive decline in patients following inflammatory triggers such as surgery or chemotherapy, which can lead to conditions like postoperative cognitive dysfunction (POCD) and other cognitive disorders.

Innovation Solution

Administering therapeutically effective amounts of apoptotic bodies, particularly from mesenchymal stem cells, either alone or in combination with immature dendritic cells, before, during, or after the inflammatory trigger to mitigate cognitive decline.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional methods are used to treat cognitive decline, then treatment options are limited, but cognitive outcomes remain inadequate

Engineering Contradiction:

Improvecognitive outcomesVSAvoidtreatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by administering apoptotic bodies before the inflammatory trigger (surgery or chemotherapy) to prevent cognitive decline rather than treating it after onset. This prophylactic approach is demonstrated in embodiments where apoptotic bodies are given preoperatively or before chemotherapy cycles, establishing protective effects before cognitive dysfunction can develop.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses apoptotic bodies as an intermediary substance that mediates between the inflammatory trigger and cognitive outcomes. These apoptotic bodies act as a biological mediator that modulates the inflammatory response and protects neural tissue, providing a novel mechanism that bridges the gap between conventional treatments and improved cognitive outcomes.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If apoptotic bodies are administered to prevent cognitive decline, then cognitive outcomes improve, but treatment complexity increases

Engineering Contradiction:

Improvecognitive outcomesVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies the extraction principle by isolating and using only the beneficial component (apoptotic bodies) from the complex process of cell death. Instead of using whole cells or complex therapeutic regimens, the invention extracts the specific apoptotic bodies that contain protective signals, simplifying the treatment while maintaining efficacy.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs a disposable approach by using apoptotic bodies that are administered as a single-use or limited-course therapy. The apoptotic bodies perform their protective function and are then naturally cleared by the body, eliminating the need for long-term maintenance treatments or complex monitoring systems.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If apoptotic bodies are administered after inflammatory trigger, then cognitive decline is reduced, but timing precision is required

Engineering Contradiction:

Improvecognitive protectionVSAvoidadministration timing

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent primarily applies preliminary action by administering apoptotic bodies before the inflammatory trigger to establish protective effects in advance. This timing strategy eliminates the need for precise post-event administration, as the protective mechanism is already in place before surgery or chemotherapy begins.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses beforehand cushioning by preparing and administering apoptotic bodies prior to the inflammatory insult, creating a protective buffer that cushions the brain against the upcoming inflammatory stress. This pre-positioning of protective agents ensures immediate effect when the inflammatory trigger occurs.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The administration of apoptotic bodies helps in reducing the severity and duration of cognitive impairments associated with inflammatory triggers, improving cognitive outcomes and quality of life for patients by addressing the underlying inflammatory response.

Implementation Method 1

Methodology Applied

Scientific EffectInflammation modulation:

Data Source

PatentUS20230277598A1Treatment of trauma associated cognitive dysfunction using mesenchymal stem cell apoptotic bodies and compositions thereof

Publication Date: 2023.09.07 THERAPEUTIC SOLUTIONS INTERNATIONAL INC

AI summary

Disclosed are means, treatments and compositions of matter useful for treatment of chemotherapy/radiotherapy associated cognitive dysfunction. In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse cognitive dysfunction associated with chemotherapy and/or radiation therapy. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of neuroregeneration directly or indirectly.